Needham & Company analyst Serge Belanger reiterated a Buy rating and $28 price target on Collegium Pharmaceutical (NASDAQ: COLL) after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE